Boehringer buys Swiss biotech in its latest M&A deal, going the next-gen cancer vaccine route
Boehringer Ingelheim has snapped up a Swiss biotech startup and added their group as a new platform for the oncology pipeline.
The German biopharma company has bagged Geneva-based AMAL Therapeutics, paying out an unspecified upfront in a $358 million deal — cash, milestones and everything else, all in. Plus there’s 100 million euros on the line for commercial milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.